> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# State Street Holds 5.1% Of Biogen With A Smaller Voting Position
- URL: https://www.bullished.co/state-street-holds-5-1-of-biogen-with-a-smaller-voting-position-e093c349/
- Published: 2026-11-10T12:24:25.000Z
- Updated: 2026-11-10T12:24:25.000Z
- Description: The reported holding covered 7,570,589 shares, with shared voting authority over 4,863,692.
- Author: Matteo Parrino
- Tags: SEC Filings, BIIB, Industry: Healthcare

State Street reported a [5.1% stake](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000623/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) in [Biogen](https://www.bullished.co/tag/biib/), which develops and sells treatments for serious diseases, but its voting authority covered fewer shares than its ownership position. The passive ownership disclosure filed Tuesday put the holding at 7,570,589 common shares as of September 30, 2026.

## Ownership Exceeds Voting Authority

State Street had [shared voting authority](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000623/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) over 4,863,692 shares. It also shared authority to sell or otherwise dispose of 7,562,236 shares, with neither voting nor disposal authority held solely by State Street.

The 5.1% figure measures beneficial ownership of Biogen's common-stock class; it does not mean State Street can vote that entire position. State Street certified that the securities were bought and held as part of its ordinary business, rather than for changing or influencing Biogen's control.

## Lupus Results In The Backdrop

Biogen's business centers on neurology, specialized immunology and rare diseases. Its treatments span multiple sclerosis, spinal muscular atrophy, Friedreich's ataxia and ALS; it also works with Eisai on LEQEMBI for Alzheimer's disease and Supernus on ZURZUVAE for postpartum depression.

TYSABRI and SPINRAZA each accounted for more than 10.0% of Biogen's total revenue in 2025, 2024 and 2023\. Biogen's market value was $37.7 billion as of 7:19 a.m. ET Tuesday.

On Monday, Biogen and UCB published [additional lupus analysis](https://www.globenewswire.com/news-release/2026/11/09/3398047/0/en/acr-2026-dapirolizumab-pegol-associated-with-greater-treatment-response-rates-versus-placebo-in-sle-using-novel-treatment-response-measure.html?ref=bullished.co) from their late-stage trial, which met its main goal. The analysis examined improvement across organ domains affected by the disease.

Through week 48, about 61% of patients given dapirolizumab pegol plus standard care improved in at least half of those domains. The corresponding figure was about 43% for patients given placebo plus standard care.

The lupus analysis was conducted after the trial, and its authors said the response measure needs further validation.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — STATE STREET CORPORATION re: BIOGEN INC (BIIB)](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000623/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [Oklahoma Firefighters Pension and Retirement System v. Biogen Inc. et al](https://www.law360.com/cases/620191a078cd6102cfe57616/articles?ref=bullished.co) — law360.com
- [Biogen Inc. (NASDAQ:BIIB) : Articles :: Law360](https://www.law360.com/companies/biogen-inc?ref=bullished.co) — law360.com
- [IN RE: BIOGEN INC. SECURITIES LITIGATION](https://www.law360.com/cases/55d387adacb16a0e74000001/articles?ref=bullished.co) — law360.com
- [ACR 2026: Dapirolizumab Pegol Associated with Greater](https://www.globenewswire.com/news-release/2026/11/09/3398047/0/en/acr-2026-dapirolizumab-pegol-associated-with-greater-treatment-response-rates-versus-placebo-in-sle-using-novel-treatment-response-measure.html?ref=bullished.co) — globenewswire.com

### More on Biogen

- [Biogen Says Spinraza's Third Quarter Got A One-Time Lift, With Fourth-Quarter Growth Guided To A Mid-Single-Digit Rise](https://www.bullished.co/biogen-says-spinrazas-third-quarter-got-a-one-time-lift-with-fourth-quarter-growth-guided-ce4b517b/)
- [Biogen CEO Says He 'Always Hated' Buying Late-Stage Drugs And Will Chase Early-Stage Deals](https://www.bullished.co/biogen-ceo-says-he-always-hated-buying-late-stage-drugs-and-will-chase-early-stage-deals-b30240d1/)
- [Biogen Swings To A $20.6 Million Quarterly Loss On A $283.8 Million RayThera Charge](https://www.bullished.co/biogen-swings-to-a-20-6-million-quarterly-loss-on-a-283-8-million-raythera-charge-08233730/)

[All Biogen (BIIB) coverage →](https://www.bullished.co/tag/biib/)